Loading…
Loading…
NIKA does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for NIKA and 80,000+ other tickers.
See exactly how NIKA's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for NIKA and 80,000+ other tickers.
Nika Pharmaceuticals Inc., a pharmaceutical enterprise headquartered in Henderson, Nevada, focuses on the creation of medications to address a broad spectrum of health conditions. Its research and development efforts target serious diseases including HIV/AIDS, hepatitis B and C, rheumatoid arthritis, cancer, and diabetes. The company's product line features antiviral treatments and nutritional supplements, notably providing a specialized thymus nuclear glycoprotein for the management of HIV. Originally established in 2000, the organization was previously known as Centennial Growth Equities Inc. before adopting its current name, Nika Pharmaceuticals, Inc., in May 2022.
Nika Pharmaceuticals, Inc. (OTCQB: NIKA) updates its shareholders regarding ongoing negotiations for up to 50 million USD and expected funding timeline.
HENDERSON, Nev., June 04, 2026 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCQB: NIKA) is currently engaged in active discussions with several investors from Europe and the US who have demonstrated significant interest in NIKA; negotiations with two of these parties are in advanced stages.
HENDERSON, Nev., March 06, 2026 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCQB: NIKA) announces that it has signed a consultancy agreement with MD Global Partners LLC, a leading Manhattan-based investment bank.
HENDERSON, Nev., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCQB: NIKA) appeared on The Street Reports podcast where CEO Dimitar Savov shared the progress the company has made thus far and outlined what is expected for 2026, which will be a crucial year for the company.
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com